{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:45:41Z","timestamp":1790343941067,"version":"4.1.0"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-024-03793-4","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T14:06:41Z","timestamp":1726495601000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Recent clinical researches and technological development in TIL therapy"],"prefix":"10.1007","volume":"73","author":[{"given":"Satoko","family":"Matsueda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuli","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"issue":"4770","key":"3793_CR1","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.3489291","volume":"233","author":"SA Rosenberg","year":"1986","unstructured":"Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233(4770):1318\u20131321","journal-title":"Science"},{"issue":"8","key":"3793_CR2","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.jcyt.2014.02.004","volume":"16","author":"M Donia","year":"2014","unstructured":"Donia M, Larsen SM, Met O, Svane IM (2014) Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor. Cytotherapy 16(8):1117\u20131120","journal-title":"Cytotherapy"},{"issue":"2","key":"3793_CR3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1080\/14653240802590391","volume":"11","author":"MJ Besser","year":"2009","unstructured":"Besser MJ, Schallmach E, Oved K, Treves AJ, Markel G, Reiter Y, Schachter J (2009) Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy. Cytotherapy 11(2):206\u2013217","journal-title":"Cytotherapy"},{"key":"3793_CR4","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3389\/fimmu.2017.00908","volume":"8","author":"MA Forget","year":"2017","unstructured":"Forget MA, Tavera RJ, Haymaker C, Ramachandran R, Malu S, Zhang M, Wardell S, Fulbright OJ, Toth CL, Gonzalez AM, Thorsen ST, Flores E, Wahl A, Peng W, Amaria RN, Hwu P (2017) A novel method to generate and expand clinical-grade, genetically modified. Tumor-Infiltrating Lymph Front Immunol 8:908","journal-title":"Tumor-Infiltrating Lymph Front Immunol"},{"key":"3793_CR5","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3389\/fimmu.2020.01215","volume":"11","author":"V Bianchi","year":"2020","unstructured":"Bianchi V, Harari A, Coukos G (2020) Neoantigen-specific adoptive cell therapies for cancer: making T-cell products more personal. Front Immunol 11:1215","journal-title":"Front Immunol"},{"issue":"4","key":"3793_CR6","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1208\/s12248-016-9935-9","volume":"18","author":"A Fouad","year":"2016","unstructured":"Fouad A (2016) Cell-based therapies formulations: unintended components. AAPS J 18(4):844\u2013848","journal-title":"AAPS J"},{"issue":"10","key":"3793_CR7","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s11626-017-0201-y","volume":"53","author":"JM Baust","year":"2017","unstructured":"Baust JM, Campbell LH, Harbell JW (2017) Best practices for cryopreserving, thawing, recovering, and assessing cells. In Vitro Cell Dev Biol Anim 53(10):855\u2013871","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"3793_CR8","unstructured":"Pellegrino S, Saunders J (2023) Iovance biotherapeutics announces US food and drug administration acceptance of the biologics license application of lifileucel for the treatment of advanced melanoma. IOVANCE"},{"issue":"4","key":"3793_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00428-018-2484-0","volume":"474","author":"MW Rohaan","year":"2019","unstructured":"Rohaan MW, Wilgenhof S, Haanen JBAG (2019) Adoptive cellular therapies: the current landscape. Virchows Arch 474(4):449\u2013461","journal-title":"Virchows Arch"},{"issue":"5","key":"3793_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL et al (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378(5):439\u2013448","journal-title":"N Engl J Med"},{"issue":"1","key":"3793_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2018","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P et al (2018) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol 20(1):31\u201342","journal-title":"Lancet Oncol"},{"issue":"10254","key":"3793_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254):839\u2013852","journal-title":"Lancet"},{"issue":"14","key":"3793_CR13","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS et al (2020) KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 382(14):1331\u20131342","journal-title":"N Engl J Med"},{"issue":"8","key":"3793_CR14","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K et al (2021) Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384(8):705\u2013716","journal-title":"N Engl J Med"},{"issue":"6","key":"3793_CR15","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, Avigan D, Deol A, Htut M, Lesokhin A, Munshi NC, O\u2019Donnell E, Stewart AK, Schecter JM, Goldberg JD, Goldberg JD et al (2023) Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 41(6):1265\u20131274","journal-title":"J Clin Oncol"},{"key":"3793_CR16","doi-asserted-by":"publisher","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","volume":"14","author":"A Mitra","year":"2023","unstructured":"Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B (2023) From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol 14:1188049","journal-title":"Front Immunol"},{"key":"3793_CR17","doi-asserted-by":"publisher","first-page":"1216829","DOI":"10.3389\/fonc.2023.1216829","volume":"13","author":"DJ Schendel","year":"2023","unstructured":"Schendel DJ (2023) Evolution by innovation as a driving force to improve TCR-T therapies. Front Oncol 13:1216829","journal-title":"Front Oncol"},{"issue":"13","key":"3793_CR18","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.7150\/thno.84710","volume":"13","author":"B Zhang","year":"2023","unstructured":"Zhang B, Ren Z, Zhao J, Zhu Y, Huang B, Xiao C, Zhang Y, Deng J, Mao L, Tang L, Lan D, Gao L, Zhang H, Chen G, Luo OJ (2023) Global analysis of HLA-A2 restricted MAGE-A3 tumor antigen epitopes and corresponding TCRs in non-small cell lung cancer. Theranostics 13(13):4449\u20134468","journal-title":"Theranostics"},{"issue":"8","key":"3793_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101159","volume":"4","author":"R Al-Marayaty","year":"2023","unstructured":"Al-Marayaty R, Pollack SM (2023) Pushing forward in sarcoma with a new TCR targeting NY-ESO-1. Cell Rep Med 4(8):101159","journal-title":"Cell Rep Med"},{"issue":"8","key":"3793_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101133","volume":"4","author":"Q Pan","year":"2023","unstructured":"Pan Q, Weng D, Liu J, Han Z, Ou Y, Xu B, Peng R, Que Y, Wen X, Yang J, Zhong S, Zeng L, Chen A, Gong H, Lin Y, Chen J, Ma K, Lau JYN, Li Y, Fan Z, Zhang X (2023) Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A\u221702:01 patients with advanced soft tissue sarcoma. Cell Rep Med 4(8):101133","journal-title":"Cell Rep Med"},{"issue":"2","key":"3793_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40264-018-0779-3","volume":"42","author":"B Wolf","year":"2019","unstructured":"Wolf B, Zimmermann S, Arber C, Irving M, Trueb L, Coukos G (2019) Safety and tolerability of adoptive cell therapy in cancer. Drug Saf 42(2):315\u2013334","journal-title":"Drug Saf"},{"issue":"1","key":"3793_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s40425-018-0391-1","volume":"6","author":"MW Rohaan","year":"2018","unstructured":"Rohaan MW, van den Berg JH, Kvistborg P, Haanen JBAG (2018) Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option. J Immunother Cancer 6(1):102","journal-title":"J Immunother Cancer"},{"key":"3793_CR23","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/EDBK_238691","volume":"39","author":"B Santomasso","year":"2019","unstructured":"Santomasso B, Bachier C, Westin J, Rezvani K, Shpall EJ (2019) The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book 39:433\u2013444","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10","key":"3793_CR24","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-22-1922","volume":"29","author":"AB Warner","year":"2023","unstructured":"Warner AB, Corrie PG, Hamid O (2023) Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future. Clin Cancer Res 29(10):1835\u20131854","journal-title":"Clin Cancer Res"},{"issue":"24","key":"3793_CR25","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","volume":"39","author":"AA Sarnaik","year":"2021","unstructured":"Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, Thomas SS, Domingo-Musibay E, Pavlick AC, Whitman ED, Martin-Algarra S, Corrie P, Curti BD, Ol\u00e1h J, Lutzky J et al (2021) Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol 39(24):2656\u20132666","journal-title":"J Clin Oncol"},{"issue":"2","key":"3793_CR26","doi-asserted-by":"publisher","first-page":"e000668","DOI":"10.1136\/jitc-2020-000668","volume":"8","author":"TH Borch","year":"2020","unstructured":"Borch TH, Andersen R, Ellebaek E, Met \u00d6, Donia M, Svane IM (2020) Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma. J Immunother Cancer 8(2):e000668","journal-title":"J Immunother Cancer"},{"issue":"6","key":"3793_CR27","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/PPO.0000000000000157","volume":"21","author":"JC Yang","year":"2015","unstructured":"Yang JC (2015) Toxicities associated with adoptive T-cell transfer for cancer. Cancer J 21(6):506\u2013509","journal-title":"Cancer J"},{"issue":"18","key":"3793_CR28","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","volume":"33","author":"JS Weber","year":"2015","unstructured":"Weber JS, Yang JC, Atkins MB, Disis ML (2015) Toxicities of immunotherapy for the practitioner. J Clin Oncol 33(18):2092\u20132099","journal-title":"J Clin Oncol"},{"issue":"13","key":"3793_CR29","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17(13):4550\u20134557","journal-title":"Clin Cancer Res"},{"issue":"14","key":"3793_CR30","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","volume":"33","author":"S Stevanovi\u0107","year":"2015","unstructured":"Stevanovi\u0107 S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS (2015) Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 33(14):1543\u20131550","journal-title":"J Clin Oncol"},{"issue":"12","key":"3793_CR31","doi-asserted-by":"publisher","first-page":"e005755","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"J Chesney","year":"2022","unstructured":"Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Hassel JC, Orloff M, Larkin J, Weber J, Furness AJS et al (2022) Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts. J Immunother Cancer 10(12):e005755","journal-title":"J Immunother Cancer"},{"issue":"15","key":"3793_CR32","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","volume":"22","author":"R Andersen","year":"2016","unstructured":"Andersen R, Donia M, Ellebaek E, Borch TH, Kongsted P, Iversen TZ, H\u00f6lmich LR, Hendel HW, Met \u00d6, Andersen MH, thor Straten P, Svane IM (2016) Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. Clin Cancer Res 22(15):3734\u20133745","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3793_CR33","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/(SICI)1097-0142(19960715)78:2<244::AID-CNCR9>3.0.CO;2-L","volume":"78","author":"GB Ratto","year":"1996","unstructured":"Ratto GB, Zino P, Mirabelli S, Minuti P, Aquilina R, Fantino G, Spessa E, Ponte M, Bruzzi P, Melioli G (1996) A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer 78(2):244\u2013251","journal-title":"Cancer"},{"issue":"20","key":"3793_CR34","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1200\/JCO.2016.66.7220","volume":"34","author":"SL Goff","year":"2016","unstructured":"Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, Zlott DA, Yang JC, Sherry RM, Kammula US, Klebanoff CA, Hughes MS, Restifo NP, Langhan MM et al (2016) Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. J Clin Oncol 34(20):2389\u20132397","journal-title":"J Clin Oncol"},{"issue":"2","key":"3793_CR35","doi-asserted-by":"publisher","first-page":"e000848","DOI":"10.1136\/jitc-2020-000848","volume":"8","author":"JH van den Berg","year":"2020","unstructured":"van den Berg JH, Heemskerk B, van Rooij N, Gomez-Eerland R, Michels S, van Zon M, de Boer R, Bakker NAM, Jorritsma-Smit A, van Buuren MM, Kvistborg P, Spits H, Schotte R, Mallo H, Karger M et al (2020) Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. J Immunother Cancer 8(2):e000848","journal-title":"J Immunother Cancer"},{"issue":"7","key":"3793_CR36","first-page":"1934","volume":"51","author":"Y Aoki","year":"1991","unstructured":"Aoki Y, Takakuwa K, Kodama S, Tanaka K, Takahashi M, Tokunaga A, Takahashi T (1991) Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res 51(7):1934\u20131939","journal-title":"Cancer Res"},{"issue":"6","key":"3793_CR37","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","volume":"24","author":"N Zacharakis","year":"2018","unstructured":"Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, Gartner J, Jia L, Trebska-McGowan K, Somerville RP, Robbins PF, Rosenberg SA et al (2018) Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med 24(6):724\u2013730","journal-title":"Nat Med"},{"issue":"8","key":"3793_CR38","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00262-018-2174-4","volume":"67","author":"R Ben-Avi","year":"2018","unstructured":"Ben-Avi R, Farhi R, Ben-Nun A, Gorodner M, Greenberg E, Markel G, Schachter J, Itzhaki O, Besser MJ (2018) Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients. Cancer Immunol Immunother 67(8):1221\u20131230","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"3793_CR39","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","volume":"27","author":"BC Creelan","year":"2021","unstructured":"Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN, Noyes DR, Montoya LB, Curry W, Pilon-Thomas SA, Chiappori AA, Tanvetyanon T et al (2021) Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med 27(8):1410\u20131418","journal-title":"Nat Med"},{"key":"3793_CR40","doi-asserted-by":"publisher","first-page":"107481","DOI":"10.1016\/j.intimp.2021.107481","volume":"94","author":"AM Aydin","year":"2021","unstructured":"Aydin AM, Hall M, Bunch BL, Branthoover H, Sannasardo Z, Mackay A, Beatty M, Sarnaik AA, Mullinax JE, Spiess PE, Pilon-Thomas S (2021) Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients. Int Immunopharmacol 94:107481","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"3793_CR41","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1007\/s00262-023-03500-9","volume":"72","author":"J Balzeau","year":"2023","unstructured":"Balzeau J, Ravindran A, Wang X, Maisuria J, Lucchesi A, Yao H, Matsueda S (2023) Successful ex vivo expansion of tumor infiltrating lymphocytes with systemic chemotherapy prior to surgical resection. Cancer Immunol Immunother 72(10):3377\u20133385","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"3793_CR42","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.1002\/mco2.213","volume":"4","author":"W Jia","year":"2023","unstructured":"Jia W, Guo H, Wang M, Li J, Yu J, Zhu H, Wu G (2023) High post-chemotherapy TIL and increased CD4+TIL are independent prognostic factors of surgically resected NSCLC following neoadjuvant chemotherapy. MedComm 4(1):e213","journal-title":"MedComm"},{"issue":"23","key":"3793_CR43","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, Borch TH, van den Berg JH, Met \u00d6, Kessels R, Foppen MHG, Granh\u00f8j JS, Nuijen B, Nijenhuis C, Jedema I, van Zon M, Scheij S, Beijnen JH, Hansen M, Voermans C et al (2022) Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N Engl J Med 387(23):2113\u20132125","journal-title":"N Engl J Med"},{"issue":"19","key":"3793_CR44","doi-asserted-by":"publisher","first-page":"5289","DOI":"10.1158\/1078-0432.CCR-21-1171","volume":"27","author":"SJ Seitter","year":"2021","unstructured":"Seitter SJ, Sherry RM, Yang JC, Robbins PF, Shindorf ML, Copeland AR, McGowan CT, Epstein M, Shelton TE, Langhan MM, Franco Z, Danforth DN, White DE, Rosenberg SA, Goff SL (2021) Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma. Clin Cancer Res 27(19):5289\u20135298","journal-title":"Clin Cancer Res"},{"issue":"15","key":"3793_CR45","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","volume":"22","author":"R Andersen","year":"2016","unstructured":"Andersen R, Donia M, Ellebaek E, Borch TH, Kongsted P, Iversen TZ, H\u00f6lmich LR, Hendel HW, Met \u00d6, Andersen MH, Straten PT, Svane IM (2016) Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. Clin Cancer Res 22(15):3734\u20133745","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3793_CR46","first-page":"3967","volume":"12","author":"M Pillai","year":"2022","unstructured":"Pillai M, Jiang Y, Lorigan PC, Thistlethwaite FC, Thomas M, Kirillova N, Bridgeman JS, Kueberuwa G, Biswas S, Velazquez P, Chonzi D, Guest RD, Roberts ZJ, Hawkins RE (2022) Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma. Am J Cancer Res 12(8):3967\u20133984","journal-title":"Am J Cancer Res"},{"key":"3793_CR47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.coi.2016.05.006","volume":"41","author":"JA Wargo","year":"2016","unstructured":"Wargo JA, Reddy SM, Reuben A, Sharma P (2016) Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol 41:23\u201331","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"3793_CR48","doi-asserted-by":"publisher","first-page":"808","DOI":"10.3390\/cells10040808","volume":"10","author":"SS Qin","year":"2021","unstructured":"Qin SS, Melucci AD, Chacon AC, Prieto PA (2021) Adoptive T cell therapy for solid tumors: pathway to personalized standard of care. Cells 10(4):808","journal-title":"Cells"},{"issue":"17","key":"3793_CR49","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.3390\/cancers14174160","volume":"14","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Deng J, Rao S, Guo S, Shen J, Du F, Wu X, Chen Y, Li M, Chen M, Li X, Li W, Gu L, Sun Y, Zhang Z, Wen Q, Xiao Z, Li J (2022) Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges. Cancers (Basel) 14(17):4160","journal-title":"Cancers (Basel)"},{"key":"3793_CR50","doi-asserted-by":"publisher","first-page":"844142","DOI":"10.3389\/fimmu.2022.844142","volume":"13","author":"B Lv","year":"2022","unstructured":"Lv B, Wang Y, Ma D, Cheng W, Liu J, Yong T, Chen H, Wang C (2022) Immunotherapy: reshape the tumor immune microenvironment. Front Immunol 13:844142","journal-title":"Front Immunol"},{"key":"3793_CR51","doi-asserted-by":"publisher","first-page":"1200646","DOI":"10.3389\/fonc.2023.1200646","volume":"13","author":"P Czajka-Francuz","year":"2023","unstructured":"Czajka-Francuz P, Prendes MJ, Mankan A, Quintana \u00c1, Pabla S, Ramkissoon S, Jensen TJ, Peir\u00f3 S, Severson EA, Achyut BR, Vidal L, Poelman M, Saini KS (2023) Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy. Front Oncol 13:1200646","journal-title":"Front Oncol"},{"issue":"12","key":"3793_CR52","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s12032-022-01842-5","volume":"39","author":"JA Faraj","year":"2022","unstructured":"Faraj JA, Al-Athari AJH, Mohie SED, Kadhim IK, Jawad NM, Abbas WJ, Jalil AT (2022) Reprogramming the tumor microenvironment to improve the efficacy of cancer immunotherapies. Med Oncol 39(12):239","journal-title":"Med Oncol"},{"key":"3793_CR53","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-3-319-67577-0_4","volume":"1036","author":"T Frankel","year":"2017","unstructured":"Frankel T, Lanfranca MP, Zou W (2017) The role of tumor microenvironment in cancer immunotherapy. Adv Exp Med Biol 1036:51\u201364","journal-title":"Adv Exp Med Biol"},{"key":"3793_CR54","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3389\/fonc.2018.00044","volume":"8","author":"JE Mullinax","year":"2018","unstructured":"Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, Brohl AS, Markowitz J, Royster E, Richards A, Stark V, Zager JS, Kelley L, Cox C, Sondak VK et al (2018) Combination of ipilimumab and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma. Front Oncol 8:44","journal-title":"Front Oncol"},{"key":"3793_CR55","doi-asserted-by":"crossref","unstructured":"O\u2019Malley D, Lee SM, Psyrri A, Sukari A, Thomas S, Wenham RM, Gogas H, Jazaeri A, Monk BJ, Rose PG, Rueda A, Finckenstein FG, Jagasia M, Fiaz R, Garelik B, Shi W, Desai A, et al (2021) Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-na\u00efve patients with advanced cancers. SITC, Washington","DOI":"10.1136\/jitc-2021-SITC2021.492"},{"key":"3793_CR56","doi-asserted-by":"crossref","unstructured":"Olson D, Hong Y, Thomas S, Mart\u00edn-Liberal J, Finckenstein FG, Wu X, Sulur G, Shi W, Larkin J (2023) Trial in progress: a phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreat. ASCO, Chicago","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9607"},{"issue":"3","key":"3793_CR57","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/00002371-199410000-00004","volume":"16","author":"RS Freedman","year":"1994","unstructured":"Freedman RS, Edwards CL, Kavanagh JJ, Kudelka AP, Katz RL, Carrasco CH, Atkinson EN, Scott W, Tomasovic B, Templin S et al (1994) Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. J Immunother Emphasis Tumor Immunol 16(3):198\u2013210","journal-title":"J Immunother Emphasis Tumor Immunol"},{"issue":"1","key":"3793_CR58","doi-asserted-by":"publisher","first-page":"e005847","DOI":"10.1136\/jitc-2022-005847","volume":"11","author":"J Karbach","year":"2023","unstructured":"Karbach J, Kiselicki D, Brand K, Wahle C, Sinelnikov E, Gustavus D, Hoffmeister H, Prisack HB, Atmaca A, J\u00e4ger E (2023) Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer. J Immunother Cancer 11(1):e005847","journal-title":"J Immunother Cancer"},{"issue":"15","key":"3793_CR59","doi-asserted-by":"publisher","first-page":"w157726","DOI":"10.1172\/JCI157726","volume":"132","author":"H Huang","year":"2022","unstructured":"Huang H, Nie CP, Liu XF, Song B, Yue JH, Xu JX, He J, Li K, Feng YL, Wan T, Zheng M, Zhang YN, Ye WJ, Li JD, Li YF, Li JY, Cao XP, Liu ZM, Zhang XS, Liu Q, Zhang X, Liu JH, Li J (2022) Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer. J Clin Invest 132(15):w157726","journal-title":"J Clin Invest"},{"issue":"6266","key":"3793_CR60","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1126\/science.aad1253","volume":"350","author":"E Tran","year":"2015","unstructured":"Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, Wunderlich JR, Somerville RP, Rosenberg SA (2015) Immunogenicity of somaticmutations in humangastrointestinal cancers. Science 350(6266):1387\u20131390","journal-title":"Science"},{"issue":"2","key":"3793_CR61","doi-asserted-by":"publisher","first-page":"e006822","DOI":"10.1136\/jitc-2023-006822","volume":"12","author":"R Amaria","year":"2024","unstructured":"Amaria R, Knisely A, Vining D, Kopetz S, Overman MJ, Javle M, Antonoff MB, Tzeng CWD, Wolff RA, Pant S, Lito K, Rangel K, Fellman B, Yuan Y, Lu KH et al (2024) Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer 12(2):e006822","journal-title":"J Immunother Cancer"},{"issue":"17","key":"3793_CR62","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.3390\/cancers14174160","volume":"14","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Deng J, Rao S, Guo S, Shen J, Du F, Wu X, Chen Y, Li M, Chen M, Li X, Li W, Gu L, Sun Y, Zhang Z, Wen Q, Xiao Z, Li J (2022) Tumor infiltrating lymphocyte (TIL) therapy for solid tumor. Cancers 14(17):4160","journal-title":"Cancers"},{"issue":"2","key":"3793_CR63","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/PPO.0b013e31824d4465","volume":"18","author":"R Wu","year":"2012","unstructured":"Wu R, Forget MA, Chacon J, Bernatchez C, Haymaker C, Chen JQ, Hwu P, Radvanyi L (2012) Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 18(2):160\u2013175","journal-title":"Cancer J"},{"issue":"24","key":"3793_CR64","doi-asserted-by":"publisher","first-page":"6122","DOI":"10.1158\/1078-0432.CCR-10-1297","volume":"16","author":"ME Dudley","year":"2010","unstructured":"Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE, Restifo NP, Wunderlich J, Prieto PA, Hong JJ, Langan RC (2010) CD8+ enriched \u201cyoung\u201d tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 16(24):6122\u20136131","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3793_CR65","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/CJI.0b013e31818403d5","volume":"31","author":"KQ Tran","year":"2008","unstructured":"Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, Robbins PF, Rosenberg SA, Dudley ME (2008) Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother 31(8):742\u2013751","journal-title":"J Immunother"},{"key":"3793_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.iotech.2019.09.003","volume":"3","author":"J Robertson","year":"2019","unstructured":"Robertson J, Salm M, Dangl M (2019) Adoptive cell therapy with tumour-infiltrating lymphocytes: the emerging importance of clonal neoantigen targets for next-generation products in non-small cell lung cancer. Immunooncol Technol 3:1\u20137","journal-title":"Immunooncol Technol"},{"issue":"6583","key":"3793_CR67","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1126\/science.abl5447","volume":"375","author":"FJ Lowery","year":"2022","unstructured":"Lowery FJ, Krishna S, Yossef R, Parikh NB, Chatani PD, Zacharakis N, Parkhurst MR, Levin N, Sindiri S, Sachs A, Hitscherich KJ, Yu Z, Vale NR, Lu YC, Zheng Z, Jia L, Gartner JJ et al (2022) Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 375(6583):877\u2013884","journal-title":"Science"},{"key":"3793_CR68","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1158\/1538-7445.AM2020-875","volume":"80","author":"E Kotsiou","year":"2020","unstructured":"Kotsiou E, Hou TZ, Robinson J, Varsani S, Oakes T, Becker PD, Patel S, Mootien J, Craig A, Robertson J, Samuel E, Reading J, Rosario LD, Haynes A, Turajlic S, Islam F et al (2020) Next generation clonal neoantigen targeting T cells, generated using the PELEUSTM bioinformatics platform and the VELOSTM manufacturing method show superior reactivity and phenotypic characteristics than classical TIL products. Cancer Res 80:875","journal-title":"Cancer Res"},{"issue":"9","key":"3793_CR69","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1097\/CJI.0b013e3181fad2b0","volume":"33","author":"T Inozume","year":"2010","unstructured":"Inozume T, Hanada KI, Wang QJ, Ahmadzadeh M, Wunderlich JR, Rosenberg SA, Yang JC (2010) Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T-cells. J Immunother 33(9):956\u2013964","journal-title":"J Immunother"},{"issue":"13","key":"3793_CR70","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1158\/0008-5472.CAN-17-0236","volume":"77","author":"SM Fernandez-Poma","year":"2017","unstructured":"Fernandez-Poma SM, Salas-Benito D, Lozano T, Casares N, Riezu-Boj JI, Manche\u00f1o U, Elizalde E, Alignani D, Zubeldia N, Otano I, Conde E, Sarobe P, Lasarte JJ, Hervas-Stubbs S (2017) Expansion of tumor-infiltrating CD8+ T cells expressing PD-1 improves the efficacy of adoptive T-cell therapy. Cancer Res 77(13):3672\u20133684","journal-title":"Cancer Res"},{"issue":"6522","key":"3793_CR71","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1126\/science.abb9847","volume":"370","author":"S Krishna","year":"2020","unstructured":"Krishna S, Lowery FJ, Copeland AR, Bahadiroglu E, Mukherjee R, Jia L, Anibal JT, Sachs A, Adebola SO, Gurusamy D, Yu Z, Hill V, Gartner JJ, Li YF, Parkhurst M, Paria B (2020) Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science 370(6522):1328\u20131334","journal-title":"Science"},{"issue":"1","key":"3793_CR72","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1038\/s41467-018-05072-0","volume":"9","author":"T Duhen","year":"2018","unstructured":"Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda NF, Goodall CP, Blair TC, Fox BA, McDermott JE, Chang SC, Grunkemeier G, Leidner R, Bell RB, Weinberg AD (2018) Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun 9(1):2724","journal-title":"Nat Commun"},{"issue":"1","key":"3793_CR73","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","volume":"131","author":"C Chester","year":"2018","unstructured":"Chester C, Sanmamed MF, Wang J, Melero I (2018) Immunotherapy targeting 4\u20131BB: mechanistic rationale, clinical results, and future strategies. Blood 131(1):49\u201357","journal-title":"Blood"},{"issue":"1","key":"3793_CR74","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1182\/blood-2006-11-056168","volume":"110","author":"M Wolfl","year":"2007","unstructured":"Wolfl M, Kuball J, Ho WY, Nguyen H, Manley TJ, Bleakley M, Greenberg PD (2007) Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 110(1):201\u2013210","journal-title":"Blood"},{"issue":"1","key":"3793_CR75","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/1078-0432.CCR-13-0945","volume":"20","author":"Q Ye","year":"2014","unstructured":"Ye Q, Song DG, Poussin M, Yamamoto T, Best A, Li C, Coukos G, Powell DJ Jr (2014) CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res 20(1):44\u201355","journal-title":"Clin Cancer Res"},{"key":"3793_CR76","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.3389\/fimmu.2017.01211","volume":"8","author":"S Seliktar-Ofir","year":"2017","unstructured":"Seliktar-Ofir S, Merhavi-Shoham E, Itzhaki O, Yunger S, Markel G, Schachter J, Besser MJ (2017) Selection of shared and neoantigen-reactive T cells for adoptive cell therapy based on CD137 separation. Front Immunol 8:1211","journal-title":"Front Immunol"},{"issue":"9","key":"3793_CR77","doi-asserted-by":"publisher","first-page":"e1476816","DOI":"10.1080\/2162402X.2018.1476816","volume":"7","author":"M Poch","year":"2018","unstructured":"Poch M, Hall M, Joerger A, Kodumudi K, Beatty M, Innamarato PP, Bunch BL, Fishman MN, Zhang J, Sexton WJ, Pow-Sang JM, Gilbert SM, Spiess PE, Dhillon J, Kelley L, Mullininax J (2018) Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer. Oncoimmunology 7(9):e1476816","journal-title":"Oncoimmunology"},{"issue":"10","key":"3793_CR78","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.4049\/jimmunol.2000759","volume":"205","author":"P Innamarato","year":"2021","unstructured":"Innamarato P, Asby S, Morse J, Mackay A, Hall M, Kidd S, Nagle L, Sarnaik AA, Pilon-Thomas S (2021) Intratumoral activation of 41BB co-stimulatory signals enhances CD8 T cell expansion and modulates tumor-infiltrating myeloid cells. J Immunol 205(10):2893\u20132904","journal-title":"J Immunol"},{"issue":"2","key":"3793_CR79","doi-asserted-by":"publisher","first-page":"e001650","DOI":"10.1136\/jitc-2020-001650","volume":"8","author":"G Leem","year":"2020","unstructured":"Leem G, Park J, Jeon M, Kim ES, Kim SW, Lee YJ, Choi SJ, Choi B, Park S, Ju YS, Jung I, Kim S, Shin EC, Lee JY, Park SH (2020) 4\u20131BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39+ CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. J Immunother Cancer 8(2):e001650","journal-title":"J Immunother Cancer"},{"issue":"24","key":"3793_CR80","doi-asserted-by":"publisher","first-page":"7189","DOI":"10.1158\/0008-5472.CAN-12-4174","volume":"73","author":"BD Curti","year":"2013","unstructured":"Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwsen T, Fox BA, Moudgil T, Miller W, Haley D, Coffey T, Fisher B (2013) OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res 73(24):7189\u20137198","journal-title":"Cancer Res"},{"issue":"13","key":"3793_CR81","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.1158\/0008-5472.CAN-07-6484","volume":"68","author":"MJ Gough","year":"2008","unstructured":"Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, Weinberg AD (2008) OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res 68(13):5206\u20135215","journal-title":"Cancer Res"},{"key":"3793_CR82","first-page":"LB","volume":"78","author":"K Ritthipichai","year":"2018","unstructured":"Ritthipichai K, Machin M, Fardis M, Chartier C (2018) Anti-OX40 agonistic antibody enhances ex vivo CD8+ TIL expansion with increased T-cell effector function. Am Assoc Cancer Res 78:LB-110","journal-title":"Am Assoc Cancer Res"},{"issue":"2","key":"3793_CR83","first-page":"107","volume":"35","author":"L Tas","year":"2023","unstructured":"Tas L, Jedema I, Haanen JBAG (2023) Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers. Curr Opin Oncol 35(2):107\u2013113","journal-title":"Curr Opin Oncol"},{"issue":"7","key":"3793_CR84","doi-asserted-by":"publisher","first-page":"e003750","DOI":"10.1136\/jitc-2021-003750","volume":"10","author":"SM Fix","year":"2022","unstructured":"Fix SM, Forget MA, Sakellariou-Thompson D, Wang Y, Griffiths TM, Lee M, Haymaker CL, Dominguez AL, Basar R, Reyes C, Kumar S, Meyer LA, Hwu P, Bernatchez C, Jazaeri AA (2022) CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-\u03b2 signaling. J Immunother Cancer 10(7):e003750","journal-title":"J Immunother Cancer"},{"key":"3793_CR85","doi-asserted-by":"crossref","unstructured":"Arthofer E, Chakraborty K, Viney L, Johnson MJ, Webber BR, Moriarity BS, Lou E, Choudhry M, Klebanoff CA, Henley T (2021) Genetic editing of CISH enhances T cell effector programs independently of 1 immune checkpoint cell surface ligand expression. biRxiv","DOI":"10.1101\/2021.08.17.456714"},{"issue":"10","key":"3793_CR86","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.medj.2022.07.008","volume":"3","author":"DC Palmer","year":"2022","unstructured":"Palmer DC, Webber BR, Patel Y, Johnson MJ, Kariya CM, Lahr WS, Parkhurst MR, Gartner JJ, Prickett TD, Lowery FJ, Kishton RJ, Gurusamy D, Franco Z, Vodnala SK, Diers MD et al (2022) Internal checkpoint regulates T cell neoantigen reactivity and 701 susceptibility to PD-1 blockade. Med 3(10):682-704.e8","journal-title":"Med"},{"key":"3793_CR87","doi-asserted-by":"crossref","unstructured":"Jaffer T, Ma D (2016) The emerging role of chemokine receptor CXCR2 in cancer progression. Translational Cancer Research","DOI":"10.21037\/tcr.2016.10.06"},{"issue":"16","key":"3793_CR88","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1089\/10430340260355374","volume":"13","author":"MH Kershaw","year":"2002","unstructured":"Kershaw MH, Wang G, Westwood JA, Pachynski RK, Tiffany HL, Marincola FM, Wang E, Young HA, Murphy PM, Hwu P (2002) Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther 13(16):1971\u20131980","journal-title":"Hum Gene Ther"},{"issue":"22","key":"3793_CR89","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-10-0712","volume":"16","author":"W Peng","year":"2010","unstructured":"Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M, Whittington M, Yang Y, Overwijk WW, Liz\u00e9e G, Hwu P (2010) Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res 16(22):5458\u20135468","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3793_CR90","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1084\/jem.178.4.1223","volume":"178","author":"MJ Brunda","year":"1993","unstructured":"Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178(4):1223\u20131230","journal-title":"J Exp Med"},{"issue":"7","key":"3793_CR91","first-page":"2541","volume":"90","author":"JP Leonard","year":"1997","unstructured":"Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL (1997) Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90(7):2541\u20132548","journal-title":"Blood"},{"issue":"10","key":"3793_CR92","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","volume":"21","author":"L Zhang","year":"2015","unstructured":"Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, Nahvi AV, Ngo LT, Sherry RM, Phan GQ, Hughes MS, Kammula US, Feldman SA, Toomey MA, Kerkar SP, Restifo NP, Yang JC, Steven A (2015) Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res 21(10):2278\u20132288","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3793_CR93","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/2767-9764.CRC-22-0265","volume":"3","author":"SMR Islam","year":"2023","unstructured":"Islam SMR, Maeda T, Tamaoki N, Good ML, Kishton RJ, Paria BC, Yu Z, Bosch-Marce M, Bedanova NM, Liu C, Kruhlak MJ, Restifo NP, Vizcardo R (2023) Reprogramming of tumor-reactive tumor-infiltrating lymphocytes to human-induced pluripotent stem cells. Cancer Res Commun 3(5):917\u2013932","journal-title":"Cancer Res Commun"},{"key":"3793_CR94","doi-asserted-by":"crossref","unstructured":"Harris BD, Patel Y, Ha NH, Kritikou J, Zhao L, Lou S, Siebert S, Fu-Sum E, Kishton R, Sundar P, Vodnala SK, Potluri S (2022) Epi-R\u2122 technology produces a polyclonal TIL product (LYL845) with diverse tumor-reactive clones that have stem-like qualities and anti-tumor function","DOI":"10.1136\/jitc-2022-SITC2022.0340"},{"key":"3793_CR95","doi-asserted-by":"crossref","unstructured":"Patel Y, Harris BD, Bedard M, Kritikou J, Casas MG, Harms C, De Francesco M, Sundar P, Restifo NP, Lee G, Potluri S, Vodnala SK (2022) Epi-R\u2122 technology produces a polyclonal TIL product (LYL845) with a greater expansion success rate across hot and cold tumors, improved product phenotype, and maintenance of TCR diversity. SITC","DOI":"10.1136\/jitc-2022-SITC2022.0370"},{"key":"3793_CR96","unstructured":"Bridgeman J (2023) A CD28\/CD40 based chimeric costimulatory antigen receptor (CoStAR\u2122) targeting folate receptor alpha enhances anti-tumour activity of tumour infiltrating lymphocytes. BSGCT annual conference"},{"issue":"12","key":"3793_CR97","first-page":"e20220745","volume":"219","author":"J Shen","year":"2022","unstructured":"Shen J, Zou Z, Guo J, Cai Y, Xue D, Liang Y, Wang W, Fu YX, Peng H (2022) An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery. Skip Nav Destination 219(12):e20220745","journal-title":"Skip Nav Destination"},{"issue":"8","key":"3793_CR98","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.3390\/jcm9082628","volume":"9","author":"SA Hong","year":"2020","unstructured":"Hong SA, Hwang HW, Kim MK, Lee TJ, Yim K, Won HS, Sun DS, Kim EY, Ko YH (2020) High endothelial venule with concomitant high CD8+ tumor-infiltrating lymphocytes is associated with a favorable prognosis in resected gastric cancer. J Clin Med 9(8):2628","journal-title":"J Clin Med"},{"issue":"10","key":"3793_CR99","doi-asserted-by":"publisher","first-page":"e003353","DOI":"10.1136\/jitc-2021-003353","volume":"9","author":"HS Park","year":"2021","unstructured":"Park HS, Kim YM, Kim S, Lee WS, Kong SJ, Yang H, Kang B, Cheon J, Shin SJ, Kim C, Chon HJ (2021) High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer. J Immunother Cancer 9(10):e003353","journal-title":"J Immunother Cancer"},{"issue":"11","key":"3793_CR100","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1158\/2326-6066.CIR-17-0131","volume":"5","author":"EJ Colbeck","year":"2017","unstructured":"Colbeck EJ, Jones E, Hindley JP, Smart K, Schulz R, Browne M, Cutting S, Williams A, Parry L, Godkin A, Ware CF, Ager A, Gallimore A (2017) Treg depletion licenses T cell-driven HEV neogenesis and promotes tumor destruction. Cancer Immunol Res 5(11):1005\u20131015","journal-title":"Cancer Immunol Res"},{"issue":"21","key":"3793_CR101","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1158\/0008-5472.CAN-12-1912","volume":"72","author":"JP Hindley","year":"2012","unstructured":"Hindley JP, Jones E, Smart K, Bridgeman H, Lauder SN, Ondondo B, Cutting S, Ladell K, Wynn KK, Withers D, Price DA, Ager A, Godkin AJ, Gallimore AM (2012) T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion. Cancer Res 72(21):5473\u20135482","journal-title":"Cancer Res"},{"issue":"3","key":"3793_CR102","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.trecan.2020.10.001","volume":"7","author":"S Milutinovic","year":"2021","unstructured":"Milutinovic S, Abe J, Godkin A, Stein JV, Gallimore A (2021) The dual role of high endothelial venules in cancer progression versus immunity. Trends Cancer 7(3):214\u2013225","journal-title":"Trends Cancer"},{"key":"3793_CR103","doi-asserted-by":"publisher","first-page":"100332","DOI":"10.1016\/j.jbo.2020.100332","volume":"25","author":"C Wang","year":"2020","unstructured":"Wang C, Li M, Wei R, Wu J (2020) Adoptive transfer of TILs plus anti-PD1 therapy: an alternative combination therapy for treating metastatic osteosarcoma. J Bone Oncol 25:100332","journal-title":"J Bone Oncol"},{"issue":"24","key":"3793_CR104","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.1158\/1078-0432.CCR-22-2103","volume":"28","author":"MS Hall","year":"2022","unstructured":"Hall MS, Mullinax JE, Cox CA, Hall AM, Beatty MS, Blauvelt J, Innamarato P, Nagle L, Branthoover H, Wiener D, Schachner B, Martinez AJ, Richards AD, Rich CJ et al (2022) Combination nivolumab, CD137 agonism, and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma. Clin Cancer Res 28(24):5317\u20135329","journal-title":"Clin Cancer Res"},{"issue":"10","key":"3793_CR105","doi-asserted-by":"publisher","first-page":"e003499","DOI":"10.1136\/jitc-2021-003499","volume":"9","author":"AH Kverneland","year":"2021","unstructured":"Kverneland AH, Chamberlain CA, Borch TH, Nielsen M, M\u00f8rk SK, Kjeldsen JW, Lorentzen CL, J\u00f8rgensen LP, Riis LB, Yde CW, Met \u00d6, Donia M et al (2021) Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types. J Immunother Cancer 9(10):e003499","journal-title":"J Immunother Cancer"},{"issue":"5","key":"3793_CR106","doi-asserted-by":"publisher","first-page":"e001743","DOI":"10.1136\/jitc-2020-001743","volume":"9","author":"A Nissani","year":"2021","unstructured":"Nissani A, Lev-Ari S, Meirson T, Jacoby E, Asher N, Ben-Betzalel G, Itzhaki O, Shapira-Frommer R, Schachter J, Markel G, Besser MJ (2021) Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy. J Immunother Cancer 9(5):e001743","journal-title":"J Immunother Cancer"},{"issue":"8","key":"3793_CR107","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1111\/cas.15009","volume":"112","author":"I Hirai","year":"2021","unstructured":"Hirai I, Funakoshi T, Kamijuku H, Fukuda K, Mori M, Sakurai M, Koda Y, Kato J, Mori T, Watanabe N, Noji S, Yaguchi T, Iwata T, Ohta S, Fujita T, Tanosaki R et al (2021) Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors. Cancer Sci 112(8):3163\u20133172","journal-title":"Cancer Sci"},{"issue":"14","key":"3793_CR108","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.3390\/ijms21145009","volume":"21","author":"C Barbari","year":"2020","unstructured":"Barbari C, Fontaine T, Parajuli P, Lamichhane N, Jakubski S, Lamichhane P, Deshmukh RR (2020) Immunotherapies and combination strategies for immuno-oncology. Int J Mol Sci 21(14):5009","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3793_CR109","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12943-018-0864-3","volume":"17","author":"M Yi","year":"2018","unstructured":"Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, Wu K (2018) Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors. Mol Cancer 17(1):129","journal-title":"Mol Cancer"},{"issue":"3","key":"3793_CR110","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller BC, Sen DR, Abosy RA, Bi K, Virkud YV, Fleur MWL, Yates KB, Lako A, Felt K, Naik GS, Manos M, Gjini E, Kuchroo JR, Ishizuka JJ, Collier JL, Griffin GK, Maleri S et al (2019) Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol 20(3):326\u2013336","journal-title":"Nat Immunol"},{"issue":"4","key":"3793_CR111","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E et al (2018) Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175(4):998-1013.e20","journal-title":"Cell"},{"issue":"1","key":"3793_CR112","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui I, Schaeuble K, Chennupati V, Marraco SAF, Calderon-Copete S, Ferreira DP, Carmona SJ, Scarpellino L, Gfeller D, Pradervand S, Luther SA, Speiser DE, Held W (2019) Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50(1):195-211.e10","journal-title":"Immunity"},{"issue":"3","key":"3793_CR113","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jcyt.2018.11.004","volume":"21","author":"EL Hopewell","year":"2019","unstructured":"Hopewell EL, Cox C, Pilon-Thomas S, Kelley LL (2019) Tumor-infiltrating lymphocytes: Streamlining a complex manufacturing process. Cytotherapy 21(3):307\u2013314","journal-title":"Cytotherapy"},{"key":"3793_CR114","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.addr.2017.06.005","volume":"114","author":"NJ Dwarshuis","year":"2017","unstructured":"Dwarshuis NJ, Parratt K, Santiago-Miranda A, Roy K (2017) Cells as advanced therapeutics: state-of-the-art, challenges, and opportunities in large scale biomanufacturing of high-quality cells for adoptive immunotherapies. Adv Drug Deliv Rev 114:222\u2013239","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"3793_CR115","doi-asserted-by":"publisher","first-page":"32","DOI":"10.25270\/jcp.2021.12.4","volume":"7","author":"HM Guirgis","year":"2021","unstructured":"Guirgis HM (2021) Costs of extended use of the immune checkpoint inhibitors in first-line non-small cell lung cancer. J Clin Pathways 7(10):32\u201336","journal-title":"J Clin Pathways"},{"issue":"12","key":"3793_CR116","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1080\/13696998.2018.1521416","volume":"21","author":"RP Insinga","year":"2018","unstructured":"Insinga RP, Vanness DJ, Feliciano JL, Vandormael K, Traore S, Burke T (2018) Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US. J Med Econ 21(12):1191\u20131205","journal-title":"J Med Econ"},{"issue":"9","key":"3793_CR117","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jcyt.2021.04.003","volume":"23","author":"A Li","year":"2021","unstructured":"Li A, Kusuma GD, Driscoll D, Smith N, Wall DM, Levine BL, James D, Lim R (2021) Advances in automated cell washing and concentration. Cytotherapy 23(9):774\u2013786","journal-title":"Cytotherapy"},{"issue":"5","key":"3793_CR118","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/bit.28346","volume":"120","author":"S Nikita","year":"2023","unstructured":"Nikita S, Mishra S, Gupta K, Runkana V, Gomes J, Rathore AS (2023) Advances in bioreactor control for production of biotherapeutic products. Biotechnol Bioeng 120(5):1189\u20131214","journal-title":"Biotechnol Bioeng"},{"issue":"12","key":"3793_CR119","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.2217\/rme-2020-0142","volume":"15","author":"YY Wu","year":"2020","unstructured":"Wu YY, Liu D, Naing MW (2020) Development of a closed and automated bioreactor technology for cell therapy manufacturing\u2014a sharing of our journey. Regen Med 15(12):2335\u20132340","journal-title":"Regen Med"},{"issue":"6","key":"3793_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.189017","volume":"1878","author":"M Wu","year":"2023","unstructured":"Wu M, Zhou S (2023) Harnessing tumor immunogenomics: tumor neoantigens in ovarian cancer and beyond. Biochim Biophys Acta Rev Cancer 1878(6):189017","journal-title":"Biochim Biophys Acta Rev Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03793-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03793-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03793-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T12:04:55Z","timestamp":1729771495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03793-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":120,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["3793"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03793-4","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]},"assertion":[{"value":"10 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"232"}}